Literature DB >> 12791194

Dopa-responsive Dystonia in Children.

Jonathan W. Mink1.   

Abstract

Treatment of dopa-responsive dystonia is one of the more satisfying experiences in clinical neurology. The response to treatment with levodopa is usually dramatic and complete with no long-term complications. Carbidopa/levodopa is the mainstay in treating dopa-responsive dystonia. There is some experience using anticholinergic agents, but they are more likely to cause side effects and do not treat the underlying biochemical abnormality. Dopa-responsive dystonia caused by guanosine triphosphate cyclohydrolase I deficiency typically presents with dystonia in the lower extremities in the first decade of life. However, the presenting symptoms can vary. Thus, it is this author's recommendation that any child with dystonia receive a trial of carbidopa/levodopa.

Entities:  

Year:  2003        PMID: 12791194     DOI: 10.1007/s11940-003-0033-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  17 in total

1.  GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs.

Authors:  P R Jarman; O Bandmann; C D Marsden; N W Wood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

2.  Hereditary progressive dystonia with marked diurnal fluctuation.

Authors:  M Segawa; A Hosaka; F Miyagawa; Y Nomura; H Imai
Journal:  Adv Neurol       Date:  1976

3.  The long-term response to levodopa in dopa-responsive dystonia.

Authors:  W J Hwang; D B Calne; J K Tsui; R de la Fuente-Fernández
Journal:  Parkinsonism Relat Disord       Date:  2001-09       Impact factor: 4.891

Review 4.  Dopa-responsive dystonia.

Authors:  T G Nygaard; C D Marsden; R C Duvoisin
Journal:  Adv Neurol       Date:  1988

Review 5.  Dopa-responsive dystonia -- the story so far.

Authors:  O Bandmann; N W Wood
Journal:  Neuropediatrics       Date:  2002-02       Impact factor: 1.947

6.  Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene.

Authors:  H Ichinose; T Ohye; E Takahashi; N Seki; T Hori; M Segawa; Y Nomura; K Endo; H Tanaka; S Tsuji
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

7.  Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene.

Authors:  P M Knappskog; T Flatmark; J Mallet; B Lüdecke; K Bartholomé
Journal:  Hum Mol Genet       Date:  1995-07       Impact factor: 6.150

8.  Dopa-responsive dystonia: a clinical and molecular genetic study.

Authors:  O Bandmann; E M Valente; P Holmans; R A Surtees; J H Walters; R A Wevers; C D Marsden; N W Wood
Journal:  Ann Neurol       Date:  1998-10       Impact factor: 10.422

9.  Effect of tetrahydrobiopterin and 5-hydroxytryptophan on hereditary progressive dystonia with marked diurnal fluctuation: a suggestion of the serotonergic system involvement.

Authors:  A Ishida; G Takada; Y Kobayashi; I Toyoshima; K Takai
Journal:  Tohoku J Exp Med       Date:  1988-03       Impact factor: 1.848

10.  Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome.

Authors:  V Leuzzi; Ca Carducci; Cl Carducci; F Cardona; C Artiola; I Antonozzi
Journal:  Neurology       Date:  2002-10-22       Impact factor: 9.910

View more
  3 in total

1.  Case 2: Gait disturbance with unilateral intoeing.

Authors:  Melissa T Carter; Darcy Fehlings
Journal:  Paediatr Child Health       Date:  2012-12       Impact factor: 2.253

2.  L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children.

Authors:  Sandra J England; Daniel L Picchietti; Barbara Vera Couvadelli; Barbara C Fisher; Fouzia Siddiqui; Mary L Wagner; Wayne A Hening; Daniel Lewin; Glenna Winnie; Barry Cohen; Arthur S Walters
Journal:  Sleep Med       Date:  2011-04-03       Impact factor: 3.492

3.  Effects of white matter injury on resting state fMRI measures in prematurely born infants.

Authors:  Christopher D Smyser; Abraham Z Snyder; Joshua S Shimony; Tyler M Blazey; Terrie E Inder; Jeffrey J Neil
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.